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ABSTRACT
Overexpression of PARP1 exists in various cancers, including glioblastoma (GBM). 
Although PARP1 inhibition is a promising therapeutic target, no comprehensive study 
has addressed PARP1’s expression characteristics and prognostic role regarding 
molecular heterogeneity in astrocytomas including GBM. Our aim was to evaluate 
PARP1’s associations with survival, WHO grade, lineage specific markers, and GBM 
transcriptomic subtypes. We collected genomic and clinical data from the latest glioma 
datasets of The Cancer Genome Atlas and performed PARP1, ATRX, IDH1, and p53 
immunohistochemistry on GBM tissue samples. We demonstrated that PARP1 gain 
and increased mRNA expression are characteristics of high-grade astrocytomas, 
particularly of Proneural and Classical GBM subtypes. Additionally, higher PARP1 
levels exhibited an inverse correlation with patient survival (p<0.005) in the Classical 
subgroup. ATRX (p=0.006), and TP53 (p=0.015) mutations were associated with 
increased PARP1 expression and PARP1 protein level correlated with ATRX loss and 
p53 overexpression. Furthermore, higher PARP1 expression together with wildtype 
TP53 indicated shorter survival (p=0.039). Therefore, due to subtype specificity, 
PARP1 expression level and TP53 mutation status are reliable marker candidates 
to distinguish Proneural and Classical subtypes, with prognostic and therapeutic 
implications in GBM.
INTRODUCTION
Glioblastoma (GBM) is a highly aggressive and the 
most prevalent primary brain tumour in adults. GBM has a 
dismal outcome, the median survival is typically less than 
2 years [1]. The current treatment consists of maximal 
surgical resection of the tumour followed by concurrent 
chemo- (TMZ, temozolomide) and radiation therapy (RT) 
[2]. Despite extensive efforts to improve treatment, GBM 
is still resistant to current postoperative therapies making 
GBM a compelling field of cancer research [3]. Improving 
the outcome requires novel diagnostic approaches and 
effective treatment strategies [4].
The biological basis of the resistance involves 
many factors, including molecular heterogeneity, and 
impaired DNA repair mechanisms. Currently, targeting 
the poly(ADP-ribose) polymerase 1 (PARP1) DNA 
repair protein in GBM is a new and promising aspect 
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in clinical trials [5]. PARP1 is a nuclear protein, and is 
normally involved in DNA repair and the maintenance of 
genomic stability [6]. PARP1 binds to DNA strand breaks 
and produces a poly (ADP-ribose) chain from NAD+ 
substrate which signals the cell to initiate DNA damage 
repair. The role of PARP1 has been already investigated 
in brain diseases [7, 8], and its overexpression has been 
reported in various tumour types, such as breast, ovary, 
skin, colorectum, lung and brain [9–11]. Upregulated 
PARP1 can enhance the anti-apoptotic property of tumours 
resulting in resistance to DNA damaging therapeutic 
agents [12]. PARP inhibitors (PARPi) sensitize tumour 
cells to radiotherapy and to chemotherapeutic agents. The 
inhibitors attach to the catalytic domain of the protein 
thereby blocking synthesis of ADP-ribose polymers. 
Consequently, the cellular responses to DNA damage do 
not occur, leading to cell death [6].
Although all GBMs share common histological 
features, they individually vary at their molecular 
level resulting in significant differences in terms of 
prognosis and response to treatment [13]. In the last 
decade, numerous high-scale genomic profiling studies 
were performed to elucidate the biology of GBM. In 
addition, large scale functional proteomics studies were 
performed, where ENCODE software developments were 
used to integrate RNA-Seq and its correlation to protein 
expression, and regulation in GBM patients [14, 15]. 
The proteogenomic initiative runs as a HUPO (www.
HUPO.org) disease initiative, recently reported on [16]. 
In a comprehensive analysis by The Cancer Genome 
Atlas (TCGA) project, dysregulation of p53, Rb and 
receptor tyrosine kinase pathways were identified [17]. 
Recently, several glioma lineage and GBM subtype 
specific molecular alterations were described, indicating a 
diversity amid similar histological types. The identification 
of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) 
mutations was a breakthrough in the field of GBM 
research. Soon after it became an important diagnostic 
and prognostic marker in gliomas [18]. To date, GBM can 
be divided into IDH-wildtype and mutant based on their 
IDH status [19]. Furthermore, IDH1 together with Alpha 
Thalassemia/Mental Retardation Syndrome X-linked 
(ATRX ) and TP53 status are reliable diagnostic and 
prognostic markers for the astrocytoma lineage and they 
are also relevant in GBM stratification. Beyond that, GBM 
was further divided into four molecular subtypes: Classical 
(CL), Mesenchymal (ME), Proneural (PN) and Neural 
(NE), based on their chromosomal structural alterations, 
copy number alterations (CNAs), point mutation status 
and gene expression profiles [20–22].
Although the efficiency of PARP1 inhibition was 
already established in GBM, its molecular characteristics 
and prognostic role regarding molecular heterogeneity is 
not fully understood. The aim of our study is to analyse 
the role of PARP1 using the latest genomic datasets of 
the TCGA, and an independent clinical cohort (Figure 1). 
To the best of our knowledge, we hereby present the first 
comprehensive study that evaluate I) PARP1 CNAs and 
mRNA expressions, II) its usefulness in GBM subtype 
prognosis, and III) the associations of PARP1 with 
specific astrocytoma molecular markers. Finally, IV) we 
demonstrate a close link between PARP1 and TP53 that 
can serve as a prognostic and diagnostic marker for GBM.
RESULTS
Genomic and transcriptomic characteristics of 
PARP1 in GBM
We first analysed PARP1 mutations and copy 
numbers of GBM specimens in the TCGA database via 
cBioPortal (http://www.cbioportal.org/public-portal/). 
Only two PARP1 somatic mutations were observed 
(V948I and A709T) in GBM. Information on CNA data 
was available for 562 GBM samples. PARP1 exhibited a 
low-level gain and heterozygous deletions in more than 
14% and 6% of the cases, respectively. On the other hand, 
PARP1 amplification was infrequent (0.35%), however 
homozygous deletion was not observed.
Next, we examined the relative PARP1 mRNA levels 
in GBM. The database included 135 adult GBM cases 
with DNA sequencing, CNAs and mRNA expression data 
according to the screening criteria detailed in Materials 
and Methods. In addition, an increased expression was 
observed (z-score ≥1) in 20.74% (28/135) of the cases.
Lastly, for determining the possible regulation 
mechanisms associated with PARP1 expression values, 
we evaluated the correlation between CNAs and mRNA 
levels. A significant expression difference was found 
between heterozygous deletion and diploid (p=0.005), gain 
and diploid (p<0.001), as well as heterozygous deletion 
and gain statuses (p<0.001). These results demonstrate a 
close link between the copy number and gene expression 
(Figure 2A).
PARP1 levels are increased in higher grade 
astrocytomas
To examine the significance of PARP1 in malignant 
transformation of astrocytomas, the Brain Lower Grade 
Glioma (TCGA, Provisional) dataset was investigated 
through cBioPortal. Altogether, CNA data of 169 lower 
grade tumours (55 grade II and 114 grade III astrocytomas) 
were added to the 562 GBM samples. We found, that grade 
II tumours have the lowest CNA rate (0.036) followed by 
grade III astrocytomas (0.167) and grade IV GBM (0.215), 
and high PARP1 copy numbers correlate with higher 
histological grades (p<0.001) (Supplementary Figure 1). 
Homozygous deletions occurred in only 0.1% of the grade 
II tumours. PARP1 amplification was also rare, found in 
only 0.3% of GBMs. In total, mRNA expression data were 
available for 97 lower-grade astrocytomas (29 grade II 
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and 67 grade III tumours). Increased PARP1 mRNA levels 
were found in the high-grade tumours as opposed to grade 
II astrocytomas (GII vs. GIII, p=0.003, and GII vs. GIV, 
p<0.001). Although PARP1 expression was increased in 
both grade III and IV tumours, there were no significant 
changes between those two grades (Figure 2B). PARP1 
CNAs showed significant differences in distribution 
among WHO grades (p<0.001).
Mutation status of ATRX and TP53 genes are 
associated with PARP1 expressions
We evaluated the PARP1 expression signature in the 
context of the genetic heterogeneity of GBM. We analysed 
the association between PARP1 levels and the mutation 
status of astrocytoma lineage specific genes such as IDH1, 
ATRX and TP53. We discovered that samples carrying 
mutated ATRX (p=0.006) and TP53 (p=0.015) were 
associated with higher PARP1 expression levels (Table 1). 
The IDH status of GBMs did not show any association 
with PARP1 expression. The TCGA dataset contains only 
the IDH and ATRX status of the tumours (Table 2). To 
examine the association between PARP1 and TP53 status, 
cases were classified into wildtype (n=92) and mutant 
TP53 (n=43) tumours. Next, mutant TP53 samples were 
further divided into missense (n=33) and null (n=10) 
mutations in order to investigate the mutation effects on 
PARP1 expressions (Figure 3A, Table 2). PARP1 mRNA 
expression was higher in TP53 mutated cases (p=0.015) 
than in its wildtype counterpart. Importantly, there was 
Figure 1: The overview of the analysis strategy for PARP1 characterisation used in this study.
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no significant changes between missense and null TP53 
mutations (Figure 3B).
Immunohistochemical expression of PARP1 is 
correlated with ATRX and p53
We immunohistochemically studied PARP1 in 
a series of GBMs to evaluate its potential differential 
expression in association with key markers at protein 
levels. PARP1 staining was primarily localized in the 
nucleus of tumour cells, consistent with previous studies 
[11] (Figure 4). Ninety percent (54/60) of all cases were 
PARP1 positive, while 10% (6/60) were negative. The 
relationships between PARP1 and ATRX, IDH1 and p53, 
respectively, were also evaluated. In our clinical cohort, 
PARP1 IHC expression was significantly associated with 
the expression of p53 (p=0.0281) and ATRX (p=0.002) but 
not with that of IDH1 (Table 3).
PARP1 mRNA levels are increased in PN and CL 
GBM subtypes
In the exploration of the subtype-specific role of 
PARP1 in GBM, we identified that PN and CL subtypes 
showed an increased PARP1 expression (Figure 2C). More 
specifically, PN (mean z-score: 0.801) and CL (mean 
z-score: 0.375) subtypes have the highest average PARP1 
mRNA level, followed by ME (mean z-score: -0.121) and 
NE (mean z-score: -1.049), respectively.
Simultaneously, we also assessed whether PARP1 
CNAs were related to specific GBM subtypes. CNAs 
information on transcriptional subtypes were available for 
475 cases. We found that the PN subtype had the highest 
CNA rate (0.275), followed by the ME (0.226), NE 
(0.224), and CL (0.129) subtypes. PARP1 copy number 
gains were observed in all subtypes: ME (4.4%), PN 
(4.4%), CL (2.9%) and NE (2.3%). Heterozygous deletion 
of PARP1 was found in 3.4% of ME GBMs. PARP1 
amplification occurred only in CL and ME subtypes (0.2-
0.2%) (Supplementary Figure 2).
High PARP1 expression is associated with 
shorter survival in CL GBM subtype
To assess the clinical relevance of PARP1 in GBM, 
we examined the association between PARP1 mRNA 
expression and the overall survival in TCGA GBM 
samples. The mean overall survival (OS) of the TCGA 
patients was 13.3 months. GBM cases were assigned into 
PARP1-high (n=68) and PARP1-low (n=67) groups, using 
Figure 2: PARP1 copy number and expression levels in GBM subtypes and glioma WHO grades. Association between 
copy number alterations (CNAs) and mRNA expressions of PARP1 in GBM (A). PARP1 mRNA expression level z-scores in different 
grades of astrocytomas (B) and in GBM subtypes (C). The TCGA glioblastoma multiforme (WHO grade IV) & brain lower grade glioma 
(WHO grade II & III) TCGA datasets were used for the analysis.
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Table 2: Patient characteristics with available sequencing, CNA, and mRNA expression data
Brain lower grade glioma (TCGA, 
provisional) (n=97)
Glioblastoma multiforme 
(TCGA, provisional) (n=135)
Diagnosis age (years)
42.31 ± 13.14 60.59±13.48
(range: 20-74) (range: 21-89)
Overall survival (months)
24.76 ± 22.17 13.33 ± 12.64
Sex
 Female 42 45
 Male 55 90
WHO grade1
 II 29 -
 III 67 -
 IV - 135
ATRX status
 Mutant 45 7
 Wild-type 52 128
IDH status
 Mutant 66 8
 Wild-type 31 127
TP53 status
 Missense mut. 51 33
 Null mut. 14 10
 Wild-type 32 92
1WHO grade was unknown in one sample.
Table 1: Correlations between the mRNA expressions of PARP1 and key molecular glioma markers 
Key glioma 
markers N
Mean
z-score ± SE
1 p-Value
95% CI2
Lower Upper
ATRX status
 Wild-type 128 0.130 0.103 0.006 -2.124 -0.367
 Mutant 7 1.375 0.271
IDH status
 Wild-type 127 0.158 0.104 0.151 -1.457 0.228
 Mutant 8 0.772 0.369
TP53 status
 Wild-type 92 0.028 0.118 0.015 -0.943 -0.101
 Mutant 43 0.550 0.182
(Significant p-values are marked in bold.)
1Standard error; 2confidence of interval.
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Figure 3: Association between TP53 gene status and PARP1 mRNA expression in glioblastoma. PARP1 mRNA expression 
was higher in mutated TP53 cases (A), but only missense TP53 mutations showed significant difference compared to wild-type TP53 (B). 
The TCGA glioblastoma multiforme, provisional dataset was used for the analysis.
Figure 4: Immunohistochemical staining pattern for various markers in a clinical cohort of glioblastoma. 
Immunohistochemical positive and negative staining for IDH1R132H, positive and negative staining patterns of ATRX and p53, high and low 
nuclear expression of the PARP1. Original magnification: x200. Scale bar: 100 μm.
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median PARP1 mRNA expression z-score as cut off value. 
Although patients with PARP1-low expression had longer 
survival, there were no statistically significant differences 
observed between the groups (Figure 5A).
The mean OS of TCGA patients across different 
GBM subtypes was the following: CL=12.7; PN=19.8; 
ME=11.7, and NE=7.7 months. Kaplan-Meier survival 
analysis indicated that patients of the PARP1-low group 
had statistically significant shorter overall survival time 
compared with their PARP1-high counterpart (p=0.031) 
(Figure 5B). No significant differences were noted in 
the survival values between the PARP1-low, and -high 
expression cohorts of other GBM subtypes.
We also investigated whether PARP1’s genetic 
signatures were related to the clinicopathological 
characteristics of GBM patients. No significant 
associations were observed between PARP1 status and age 
and sex (Table 3).
High PARP1 level together with wildtype TP53 
predict a shorter survival in GBM
We analysed cumulative effects of p53 and PARP1 
on survival with GBM. TCGA samples were further 
classified according to their PARP1 levels and TP53 
mutation status: I) TP53mut/PARP1-high (n=29); II) 
TP53mut/PARP1-low (n=14); III) TP53WT/PARP1-high 
(n=39); and IV) TP53WT/ PARP1-low (n=53). We found, 
that GBM patients with wild-type TP53 gene and PARP1-
high level have a shorter survival (p=0.039) compared to 
the other groups (Figure 6).
PARP1 status is associated with the p53 pathway
To extend our investigations, the relationship 
between PARP1 status and the p53 pathway (CDKN1A 
(p21), MDM2, MDM4, CDKN2A (p14), and TP53BP1) 
was also examined. Regarding mRNA expressions, PARP1 
displayed significant correlation with TP53, CDKN1A, 
and TP53BP1 (Table 4, Figure 7A). Accordingly, mRNA 
expression levels of TP53 (p=0.003), and TP53BP1 
(p=0.004) were increased in PARP1-high, and CDKN1A 
(p=0.009) was increased in PARP1-low GBMs (Table 5, 
Figure 8). PARP1 levels showed correlation with copy 
number alterations of CDKN2A and MDM4 genes (Figure 
7B). More specifically, PARP1 levels were decreased in 
homozygously deleted CDKN2A (p=0.013) cases, and 
increased in cases with MDM4 gain (p=0.026) when we 
compared CNAs to the diploid variants of the genes. 
However, there was no significant association between 
MDM2 CNAs and PARP1.
DISCUSSION
Glioblastoma is one of the most assiduously studied 
cancer, yet the majority of patients are still resistant to 
Table 3: Immunohistochemical expression of PARP1 and its relationship with key molecular glioma markers 
PARP1 IHC expression
p-Value
Negative Positive
Sex
 Female 2 28 0.3894
 Male 4 26
Age
 Mean ± SD* 61.69 ± 6.45 58.52 ± 9.18 0.415
p53 expression
 Negative 4 13 0.0281
 Positive 2 41
IDH1 expression
 Negative 6 52 0.6316
 Positive 0 2
ATRX expression
 Negative 3 4 0.0020
 Positive 3 50
(Significant p-values are marked in bold).
*Standard deviation.
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Figure 6: Kaplan–Meier plot of overall survival (OS) stratified by the combination of high and low PARP1 mRNA 
expression and TP53 mutation status in GBM. The TCGA glioblastoma multiforme, provisional dataset was used for the analysis. 
(Significance was assessed by the log-rank method.)
Figure 5: Kaplan–Meier plot of overall survival (OS) stratified by high and low PARP1 mRNA expression in GBM (A) 
and in Classical GBM subgroup (B). The TCGA glioblastoma multiforme, provisional dataset was used for the analysis. (Significance 
was assessed by the log-rank method.)
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the conventional therapies [1]. Thus, the identification of 
novel biomarkers to improve the management of GBM 
is an ongoing and challenging task [4]. Although PARP1 
inhibition is a potential therapeutic target in GBM [5], 
its efficiency in the context of heterogeneity is unknown. 
Therefore, we performed an integrated bioinformatic 
analysis to evaluate PARP1’s genetic signature, and 
prognostic role regarding the molecular diversity of the 
tumour. Moreover, the correlations between PARP1 and 
three routinely used glioma markers detected by IHC were 
also tested in a clinical GBM cohort.
PARP1 is overexpressed in a variety of cancers 
[7–9], including glioblastoma [23]. Increased PARP1 
expression has been reported in paediatric high-grade 
astrocytomas, medulloblastoma, and ependymoma 
[24, 25]. Furthermore, in GBM stem cells (GSCs), the 
combination of PARPi and TMZ may represent a valuable 
strategy to reverse the stem cells’ chemo-resistance. 
Tentori et al. found, that PARPi together with TMZ 
exerted synergistic anti-tumour effects in eight out of 
ten GSC lines. Moreover, the dose reduction of TMZ is 
associated with the sensitivity of each cell line to PARPi as 
single agent [26]. Recent bioinformatic analysis of TCGA 
datasets revealed that PARP1 expression is restricted to 
higher grade tumours, and partially caused by genomic 
gain. Our findings underline that PARP1 is a marker 
candidate of higher-grade in astrocytomas, presumably 
because higher PARP1 expression facilitates the repair 
of damaged DNA and, thereby, overcomes the genetic 
instability characteristics of tumour cells [27].
Given this complex heterogeneous nature of GBM, 
it is relevant to investigate PARP1’s associations with key 
molecular markers [20, 21]. The importance of ATRX, 
IDH1, and TP53 mutations in the early development and 
the progression of astrocytic glioma lineage is well-known 
[21]. These markers also have treatment and prognostic 
relevance [21] and their mutation status can distinguish 
astrocytomas from oligodendrogliomas, as well as 
secondary from primary GBM [20]. PARP1 expression 
can occur in both IDH-wild type and mutated GBMs. 
Although there was no statistically proven association 
between PARP1 expression and IDH mutation status, a 
recent study reported that 2-hydroxyglutarate produced 
by mutated IDH induces PARP inhibitor sensitivity in 
patient-derived primary glioma cells and genetically 
matched tumour xenografts [28], which has therapeutic 
implications. On the other hand, higher PARP1 expression 
levels were tightly associated with ATRX and TP53 
mutations. ATRX alterations occur in the vast majority of 
lower-grade astrocytomas and IDH1-mutated (secondary) 
GBMs [21]. Somatic mutations in TP53 play important 
roles in gliomas, particularly in the tumorigenesis of 
lower grade astrocytomas and IDH1-mutated GBMs [4]. 
Considering that the inhibition of PARP1 enzyme is dose-
dependent [29], our results indicate that PARP inhibitors 
could be more effective in ATRX and TP53 mutated 
tumours, where PARP1 levels are usually increased.
Although high-throughput technologies are widely 
used for diagnostic purposes, there is still a need to 
improve the IHC-based stratification of GBM with the 
integration of molecular data [30]. Consistent with a 
previous study [23], PARP1 IHC expression was observed 
in the majority of clinical GBM cases. To date, the IHC 
detection of key molecular markers is possible and highly 
informative: I) using IDH1R132H mutation specific antibody 
[31]; II) most ATRX mutations result in undetectable 
ATRX expression by IHC [32]; and III) mutated p53 
protein accumulates in the nucleus of tumour cells [33]. 
Furthermore, we have demonstrated that IHC expression 
of PARP1 has an inverse correlation with ATRX, and 
linear correlation with p53 staining. These observations 
suggest that PARP1 IHC expression along with p53 
overexpression and ATRX loss can be promising predictive 
markers for PARPi in GBM.
This study investigates for the first time, to our 
knowledge, the genomic signature and prognostic 
significance of PARP1 in GBM subtypes. We hereby 
present evidence, that PARP1 can distinguish PN 
Table 4: Relationship between mRNA expressions of PARP1 and components of the p53 pathway 
Genes
Kendall's tau b Spearman's rho
Cor. coef. p-Value Cor. coef. p-Value
CDKN1A -0.187 0.001 -0.272 0.001
CDKN2A 0.028 0.629 0.047 0.587
MDM2 -0.111 0.057 -0.168 0.051
MDM4 -0.003 0.953 -0.004 0.961
TP53 0.169 0.004 0.246 0.004
TP53BP1 0.162 0.005 0.230 0.007
(Significant p-values are marked in bold).
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Figure 7: Association between PARP1 and p53 pathway in glioblastoma. A gene-gene interaction network presenting the 
correlation between PARP1 and the general members of p53 pathway in GBM according to mRNA expressions (A). The associations of 
PARP1 mRNA expression levels with CDKN2A and MDM4 copy number alterations in GBM (B). The TCGA glioblastoma multiforme, 
provisional dataset was used for the analysis.
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and CL from the other subtypes as increased PARP1 
expression was increased in these two subtypes (Figure 
2C). Our data showed that high PARP1 levels were 
associated with shorter survival in the CL group. It was 
previously presented that CL GBM is characterized by 
EGFR amplification and wild-type TP53, whereas PN 
is characterized by both IDH1 and TP53 mutations and 
PDGFRA amplification [22]. These results indicate that 
PARP1 and p53 are suitable markers to distinguish PN and 
CL subtypes, and have a prognostic relevance in GBM.
In our previous study, we demonstrated that p53 
immunopositivity correlates with TP53 mutational status, 
except for certain mutation types [33]. In GBM, we found 
that PARP1 IHC expression is correlated with p53 positive 
cases. In addition, PAPR1 mRNA levels were higher in 
samples with TP53 mutations. Importantly, the detection 
of TP53 null mutations is not accurate by IHC due to the 
truncated protein [33]. Beside the increased PARP1 levels 
in TP53 mutated cases, there was no statistical difference 
between missense and null mutated samples.
Both PARP1 and p53 play important roles in 
maintaining genomic integrity [34, 35]. Several studies 
have shown that genomic instability is usually correlated 
with poor prognosis [17, 36]. It has been previously 
reported that high level of PARP1 expression is often 
associated with poor overall survival in cancer [12]. 
Although there is a trend towards shorter survival 
of PARP1-high patients as compared to PARP1-low 
patients, no significant differences were observed 
when all GBMs were considered. Interestingly, we 
found a significantly shorter survival in PARP-high 
patients with wildtype TP53 gene (Figure 6) – possibly 
because not only TP53 mutations but also an impaired 
p53 pathway can facilitate tumour progression [37]. 
The p53 signalling pathway mediates several cellular 
processes including growth arrest, angiogenesis, 
Figure 8: The impact of PARP1 levels on p53 pathway-related genes in glioblastoma. The mRNA expression of TP53 and 
TP53BP1 was increased in PARP1-high group, whereas CDKN1A (p21) mRNA expression was higher in PARP1-low group. The TCGA 
glioblastoma multiforme, provisional dataset was used for the analysis. Level of significance: * (p < 0.05), ** (p < 0.01), and *** (p < 
0.001).
Table 5: The impact of PARP1-low and high mRNA expression levels in the p53 pathway 
Genes
PARP1 levels1
p-Value ± SE2
95% CI3
Low High Lower Upper
CDKN1A 0.075 -0.227 0.009 0.113 0.077 0.526
CDKN2A -1.117 -1.029 0.560 0.151 -0.387 0.210
MDM2 2.363 5.240 0.310 2.819 -8.472 2.717
MDM4 0.614 2.366 0.310 1.718 -5.151 1.647
TP53 -0.278 0.225 0.003 0.164 -0.828 -0.178
TP53BP1 -0.520 -0.052 0.004 0.161 -0.787 -0.150
(Significant p-values are marked in bold.)
1Mean mRNA z-scores; 2standard error; 3confidence of interval.
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apoptosis, and DNA repair [36]. It is widely accepted, 
that the progression and recurrence of glioblastoma is 
related to p53 pathway abnormalities in 87% of primary 
GBM [17]. To gain insights into the interaction between 
p53 and PARP1, we investigated and found that PARP1 
showed association with CDKN2A deletions and MDM4 
gain (both CDKN2A and MDM4 are components of the 
p53 pathway) (Figure 7B). These two genetic alterations 
are frequent in GBM, and result in abnormal p53 
signalling in tumour cells [17]. Furthermore, PARP1 
was negatively correlated with CDKN1A, which is a 
downstream member of the p53 cascade involved in 
the p53-mediated G1 arrest. This observation suggests 
that down-regulated CDKN1A cannot inhibit the Cyclin 
E-CDK2 complex in GBMs with higher PARP1 levels. 
Consequently, it can result in an augmented cell-cycle 
activity and absence of apoptosis [38]. Furthermore, 
it has been reported, that low levels of 53BP1 could 
predict resistance to PARP inhibitors, because 53BP1 
depletion reduces the cytotoxicity of PARP inhibitors 
[39]. Consistent with this notion, we found an overall 
low expression of TP53BP1 in GBM with higher levels 
in high-PARP1 cases.
In conclusion, PARP1 expression was increased 
in GBM at both mRNA and protein levels. To best of 
our knowledge, this is the first study to investigate the 
relevance of PARP1 in the context of specific molecular 
markers and subtypes of GBM. We have demonstrated 
that increased PARP1 levels show positive correlation 
with increasing tumour grades in gliomas Higher PARP1 
mRNA expression levels were associated with ATRX 
and TP53 mutations. An IHC analysis in an independent 
clinical cohort also confirmed this relationship. Our results 
revealed that PARP1 levels were increased in the PN and 
CL subtypes and correlated with shorter survival in CL 
GBMs. The observed subtype-specificity suggests that 
PARP1, together with p53, is not only a diagnostic marker 
to differentiate PN and CL subtypes, but also a predictive 
marker of shorter survival and poor therapy response 
in the CL subgroup. We also pointed out that there is a 
close interplay between PARP1 and the members of the 
p53 pathway in GBM. Our results support the therapeutic 
role of PARP inhibitors in high-grade gliomas with the 
caveat that molecular heterogeneity needs to be taken into 
account.
MATERIALS AND METHODS
TCGA datasets
Genetic alterations of PARP1, somatic mutation, 
CNA, and mRNA expression (z-score, RNA Seq V2 
RSEM) data were collected from two TCGA cohorts: 
Glioblastoma Multiforme (TCGA, Provisional) and 
Brain Lower Grade Glioma (TCGA, Provisional) using 
the cBioPortal for Cancer Genomics (www.cbioportal.
org). The relative expression of each gene and the gene 
expression distribution in a reference population were 
examined. The reference population was, either, all 
tumours that are diploid for the gene in question or, when 
available, have a normal adjacent tissue. The returned 
value indicates the number of standard deviations away 
from the mean of expression in the reference population 
(z-score) [40, 41]. In cBioPortal, copy numbers are 
computed using the GISTIC (Genomic Identification of 
Significant Targets in Cancer) algorithm, which identifies 
the putative copy number level as follows: I) high-
level amplification, II) low-level gain, III) diploid, IV) 
heterozygous deletion, or V) homozygous deletion [40, 
41].
Clinicopathological data for each patient including: 
age, sex, and survival time, was compiled from the 
TCGA portal (www.tcga-data.nci.nih.gov) and tabulated 
with genetic data. Cases for the analysis were selected 
according to the following criteria: I) only patients 
older than 18 years with available clinical data were 
included, considering that paediatric GBM represents a 
distinct molecular and genetic background (see reviews 
[42, 43]); II) oligodendrogliomas and mixed gliomas 
were omitted; III) tumours with complete genomic 
data (available somatic mutations, CNA, and mRNA 
expression information) were selected for the PARP1 
mRNA expression analysis. Altogether, 135 WHO grade 
IV glioblastoma and 96 lower grade astrocytomas (grade II 
& grade III) were assembled for the present analyses. The 
clinicopathological parameters, and key marker status of 
the cases are summarized in Table 2. GBM subtypes were 
accessible on 119 cases, with the following distribution: 
57 ME, 43 CL, 16 PN, and 5 NE.
The relationships between PARP1 mRNA expression 
and the overall patient survival were analysed by dividing 
Table 6: Specifications of the antibodies used for immunohistochemical staining
Antibodies Catalogue numbers Manufacturer Dilutions
anti-ATRX HPA001906 Sigma-Aldrich 1:1000
anti-IDH1 DIA-H09 Dianova 1:50
anti-p53 DO-7 Dako 1:700
anti-PARP1 ab6079 Abcam 1:500
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the samples into PARP1-low and PARP1-high expression 
groups, based on median mRNA expression z-score in 
TCGA dataset.
Patients with GBM
Samples were obtained from 60 patients (30 males 
and 30 female) diagnosed with GBM between 2006 and 
2014 at the first author’s affiliated institute. The mean age 
at diagnosis was 58.47 ± 9.03 years (range 30.21- 76.67 
years). After surgical removal, sections were cut and 
stained with haematoxylin-eosin (H&E) from formalin-
fixed and paraffin-embedded (FFPE) blocks. All the 
histopathological specimens were reviewed and diagnosed 
by a neuropathologist (TH) according to World Health 
Organization (WHO) criteria [19]. This research protocol 
was approved by the Institutional Review Board of the 
University of Debrecen.
Immunohistochemistry
Immunohistochemical (IHC) analysis was carried 
out as previously described [44]. Briefly, the staining 
was performed on 4-μm-thick FFPE sections using 
the manufacturers’ protocols. At first, sections were 
deparaffinised in xylene and rehydrated in a graded 
series of ethanol. Heat-induced epitope retrieval was 
performed utilizing citrate buffer (pH 6.0). After 
blocking endogenous peroxidase activity, sections 
were incubated with primary antibodies (anti-p53, 
anti-ATRX, anti-IDH1, and anti-PARP1) for 6 hours 
at room temperature. Specifications of the antibodies 
are listed in Table 6. Visualization was achieved with 
SuperSensitive™ One-step Polymer-HRP Detection 
System on Leica Bond Max™ automated IHC stainer, 
employing 3,3'-diaminobenzidine (DAB), then followed 
by counterstaining with hematoxylin. Adequate positive 
and negative controls (with omission of the primary 
antibodies) were included in the immunohistochemical 
experiments.
Cases with ≥10 % stained cells were defined as 
positive for IDH1 and p53 [20]. A cut-off point of 10 % 
was considered for the evaluation of presence or absence 
of nuclear ATRX [32]. All FFPE sections were scored in 
a blinded manner by two independent observers (MC & 
RH). The expression of all IHC markers was determined 
semi-quantitatively. Ten randomly selected high-power 
fields (or the entire tumour if the sample was smaller) 
were examined in each neurosurgical specimen.
The PARP1 expression was evaluated based on the 
distribution of positive cells. The percentage of positivity 
was scored as follows: “0” (<5%, negative), “1” (5–25%, 
sporadic), “2” (25–50%, focal), or “3” (>50%, diffuse). 
For the statistical analysis, negative and sporadic staining 
was combined as low PARP1 staining and focal and 
diffuse nuclear staining as high PARP1 staining.
Statistical and data analyses
Statistical analyses were performed using R 
software (http://www.r-project.org) and SPSS 21.0 
software (SPSS Inc., IL, USA). Comparisons between 
groups were calculated with Pearson’s Chi-square (χ2) 
test for categorical variables applying Yates' correction 
when required. The association between mRNA levels 
was measured using the Kendall’s tau and Spearmann’s 
correlation test. The difference in mRNA expression 
levels, between groups was calculated using a two-
tailed Student’s t-test. Kaplan–Meier method and Log-
Rank (Mantel-Cox) test were used for overall survival 
measurements. Differences were significant when p<0.05.
Gene-gene interaction network to demonstrate p53 
pathway and PARP1 interaction was generated by the 
GeneMania Cytoscape 3.4.0 application. Physical, co-
expression and gene-gene interactions were evaluated 
[45].
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